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ABSTRACT 
Multiple myeloma (MM) is a hematologic malignancy mostly occurring in the elderly 
and characterized by an expansion of monoclonal plasma cells in the bone marrow and 
increased monoclonal immunoglobulin in plasma. The outcome of this disease has been 
greatly improved due to introduction of new drugs. The proteasome inhibitor 
bortezomib (velcade
®
) is one of the therapeutic drugs showing very pronounced 
efficacy in the treatment of MM. However, cytotoxic effects of bortezomib on immune-
competent cells have also been observed. In the current thesis, we focus on studying 
regulatory effects of proteasome inhibition on natural killer (NK) cells and MM cell. 
We found that bortezomb induces apoptosis of NK cells at a clinically relevant dose, 
and this is mainly due to induction of reactive oxygen species (ROS). Additionally, 
bortezomib also decreased NK cell activating receptor NKp46 expression, resulting in 
impaired NKp46-mediated redirected killing activity. Bay 11-7082, a pharmacological 
inhibitor of NF-ҡB activation, also reduced NKp46 expression and suppressed 
redirected cytotoxicity, suggesting NF-ҡB was involved in the regulation of NKp46 
expression. To further study the effects of bortezomib on NK cells, we used human 
interleukin (IL)-2 activated NK cells. Down regulation of tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) expression at both protein and mRNA level in IL-2 
activated NK cells was observed after bortezomib and Bay 11-7082 treatment, 
suggesting that the proteasome is involved in the regulation of TRAIL expression 
through modulation of NF-ҡB activity. Moreover, perforin-independent killing activity 
of MM cell line RPMI8226 and U266 was also reduced after bortezomib treatment, and 
blocking cell surface-bound TRAIL impaired NK cell-mediated lysis of the TRAIL-
sensitive MM cell line, RPMI8226 cells. Next we studied a novel inhibitor of 
proteasome deubiquitination, b-AP15. We noted accumulation of polyubiquitinated 
proteins in RPMI8226 and U266 cells after b-AP15 treatment. Moreover, pro-apoptotic 
effects of b-AP15 on MM cells were also seen by detecting phosphatidylserine (PS) 
exposure, processing of pro-caspase-3, and cleavage of poly (ADP-ribose) polymerase 
(PARP); apoptosis was shown to be caspase-dependent. Additionally, b-AP15 also 
induced apoptosis in NK cells. However, the pro-apoptotic effect of b-AP15 on NK 
cells was not as pronounced as the effect of bortezomib, highlighting that b-AP15 may 
have less adverse effects on the immunosurveillance of NK cells against tumors. 
Furthermore, we evaluated a multifunctional protein HS-1 associated protein X-1 
(HAX-1), which is overexpressed in MM, and its potential role in the regulation of 
MM. Our data indicated that silencing of HAX-1 expression in the human U266 and 
RPMI8226 cells can not sensitize cells to bortezomib or b-AP15, nor to NK cell-
mediated killing. However, the ability of U266 cells to migration was reduced after 
HAX-1 knockdown, indicating that HAX-1 could play a role in regulating tumor 
metastasis. In summary, our studies contributed a better understanding of proteasome 
inhibitors as anti-cancer drugs and have provided insights into possible adverse effects 
on immune-competent cells. Our studies also identified HAX-1 as a possible target in 
MM treatment. 
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1 INTRODUCTION 
1.1 MULTIPLE MYELOMA 
1.1.1 Clinical presentation  
Multiple myeloma (MM) is a hematologic malignancy mostly occurring in the elderly 
and characterized by an expansion of monoclonal plasma cells in the bone marrow and 
increased monoclonal immunoglobulin in plasma (Suzuki 2013). It has been reported to 
cause~12,000 death per year in the United States, which account for~2% of all cancer 
death and~20% death caused by hematological malignances (Malpas, et al 1998). The 
major clinical presentations of the disease include hypercalcemia, renal failure, anemia 
and lytic bone destruction (Dolloff and Talamo 2013). Recent studies also indicated 
that MM is a precursor disease proceeded by the states of monoclonal gammopathy of 
undetermined significance (MGUS) and smoldering myeloma, which give chance to an 
early diagnose and prevention of development of MM (Landgren and Waxman 2010).  
Immunoglubin heavy locus (IgH) is a region contains a gene for the heavy chains of 
immunoglubin (Cook and Tomlinson 1995). Evidence has shown that MM is a genetic 
event. Incidence of IgH translocation presents in most MM tumors, and a variety of 
oncogenes were simultaneously dysregulated including: genes for cyclin D1 and cyclin 
D3, fibroblast growth factor 3 (FGFR3) combined with the nuclear protein MMSET 
and the transcription factor c-MAF (Bergsagel and Kuehl 2001, Kuehl and Bergsagel 
2002). Chromosomal abnormalities can be found in 90% of MM patients, which further 
support the vital role of genetic changes in the pathogenesis of MM. (Fonseca, et al 
2009) 
 
1.1.2 THERAPEUTIC APPROACHES 
Clinic outcomes of MM have been greatly improved during the past decade due to 
introduction of novel therapies. However, MM still remains incurable and most of the 
patients undergo relapse due to the presence of residual myeloma cells. (Agarwal and 
Mahadevan 2012, Kumar, et al 2008).  
 
Melphalan combined with prednisolone were the first group of therapeutic drugs 
introduced to the clinic in the 1969s for treatment of MM patients (Alexanian, et al 
1969). New therapeutic drugs including thalidomide, lenalidomide and bortezomib 
came to the clinic lately and also showed pronounced improvement for myeloma 
patients (Kumar, et al 2008). Moreover, autologous stem cell transplantation together 
with one or more novel anti-myeloma agents remains to be standard therapeutic 
strategy for younger fit MM patients (Al-Farsi 2013). All standard treatment guidelines 
for MM can be found in The Comprehensive Cancer network (NCCN) guideline 
(2013).  
 
With the remarkable progression of this disease, there are also some novel agents which 
are under clinical phase I or II trials, or basic research has found its anti-MM activity. 
Thalidomide and lenalidomide which belongs to immunomodulatory drugs (IMIDs), 
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were recently shown to have pronounced effects to human MM cells that currently 
resistant to the conventional therapy (Hideshima, et al 2000). Inhibitors of heat shock 
protein-90 (hsp90) were found to have anti-MM property by disrupting bone marrow 
stromal cell-mediated protection to MM cells, and sensitize MM cells to other cytotoxic 
chemotherapeutic drugs (Mitsiades, et al 2006). P38 mitogen-activated protein kinase 
(p38MAPK) is a downstream target to hsp27, and was reported to enhance the 
sensitivity to bortezomib-resistant MM cell lines, as well as primary patient MM cells 
(Hideshima, et al 2004). Following the success of bortezomib, more attention has been 
taken to inhibition of proteolytic pathway, and among them inhibitors for histone 
deacetylase (HDACs) especially HDAC6 inhibitor was selected as a good candidate 
(McConkey, et al 2012). Moreover, HDAC6 inhibitor alone or in combination with 
proteasome inhibitor bortezomib triggered apoptosis of MM cells via endoplasmic 
reticulum (ER) stress and activation of critical caspases, and a further in vivo study in 
severe combined immunodeficiency (SCID) mice also demonstrated its potential 
property of inhibition of tumor growth and prolonged life span of these animals (Santo, 
et al 2012). Increased evidence has shown that bone marrow microenvironment plays a 
crucial role in the pathogenesis of MM (Hideshima, et al 2007). MM growth depends 
on CXCR4 which is expressed on MM cells and stromal cell-derived factor 1α (SDF-
1α) which is presented in the bone marrow environment (Aggarwal, et al 2006). Thus, 
therapeutic targets for inhibition of interaction between CXCR4 and SDF-1α and its 
related signaling pathways were interesting for researchers to evaluate their potential 
anti-MM function (Alsayed, et al 2007, Azab, et al 2009). Given these limited 
observations, other molecular mechanisms such as the role of hypoxia, molecular 
antibodies against MM survival and other inhibitors which interfere critical pathways 
for MM survival, could also serve as targets for MM treatment.(Colla, et al 2010, 
Peterson, et al 2009, Richardson, et al 2011). With the supports of basic science, 
researchers aim to design more effective and less toxic therapeutic agents for MM 
patients.  
 
1.1.3 IMMUNITY AGAINST MULTIPLE MYELOMA 
The human immune system consists of the innate immune system and adaptive 
immune system. The innate immune system serves as the first line of immediate 
defending invaded microbes and pathogens; however, the adaptive immune system 
composed of B and T cells, serves as the second line by establishing immunologic 
memory (Schenten and Medzhitov 2011). Moreover, the two components of the 
immune system are critical players in controlling tumor progression, which was known 
as immunosurveillance (Dranoff 2004). Transformed cells or tumor cells are first 
recognized by natural killer (NK) cells, then phagocytes including macrophages and 
dendritic cells (DCs) uptake the tumor fragments lysed by NK cells, in the end 
activation of T and B cells lead to a more powerful elimination of tumor cells (Finn 
2012). Certainly, a functional immune system is required during cancer treatment 
(Paget, et al 2012). 
 
Multiple myeloma is not an exception, and to understand the function of immune 
system in MM turns out to be very important. Pessoa de Magalhães et al demonstrated 
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the fundamental role of immune system in defending tumors. They found that MM 
patients with long-term disease control had an increased number of cytotoxic CD8(+) T 
cells and NK cells, bone marrow DCs, as well as tissue microphages (Pessoa de 
Magalhães, et al 2013). Among these immune component cells, the role of NK cells in 
immunity against MM attracted particular interest due to its powerful anti-tumor 
activity (Godfrey and Benson 2012). Subsequently, NK cell related immune therapy 
was introduced into the clinic. Studies have shown that IFN-α together with IL-2 
enhanced NK cytotoxicity against MM (Shimazaki, et al 1988). Moreover, enhanced 
NK cell-mediated killing activity was also seen when using other novel anti-myeloma 
therapies, such as, immunomodulatory agent thalidomide, which could stimulate NK 
cell function by increasing IL-2 production, while the proteasome inhibitor bortezomib 
improved NK cell-mediated killing activity via decreasing the major histocompatibility 
complex (MHC) class I expression of MM cells (Davies, et al 2001, Shi, et al 2008). 
NKG2D ligand is expressed in most of multiple myeloma cells, thus, research has 
targeted NKG2D-expressing T cells as a immunotherapy for MM via NKG2D-
mediated killing activity (Barber, et al 2008). We believe that understanding effects on 
the immune system versus MM will lead to the development of improved therapies for 
this disease. 
 
1.2 APOPTOSIS PATHWAYS 
1.2.1 Apoptosis resistance in cancer 
The word apoptosis (also known as programmed cell death) derives from a Greek word 
“falling off”, as leaves from the tree. Apoptosis plays a critical role in human tissue 
development as well as maintenance of homeostasis. Cancer is a genetic disease 
(Vogelstein and Kinzler 2004), and the development of tumor is thought to be a series 
of alterations in cell physiology including: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, apoptosis resistance, limitless replicative 
potential, sustained angiogenesis, tissue invasion and metastasis; moreover, another two 
potential markers: reprogramming of energy metabolism and evading immune 
destruction were added to this list recently (Hanahan and Weinberg 2000, Hanahan and 
Weinberg 2011). Among the eight hallmarks of cancer, we will focus on apoptosis 
resistance and migration/metastasis in the current thesis. 
 
The p53 gene is consistently believed to play an critical role during cancer development, 
as half of all human cancers harbor mutations in this tumor-suppressor gene (Lane 
1992). The importance of this gene is also due to its regulatory function of other genes 
such as pro-apoptotic gene BAX (Miyashita and Reed 1995), and BH3-only proteins 
which triggers the activation of BAX, resulting in the intrinsic apoptosis (which will be 
discussed below) (Chipuk, et al 2004). Of note, a recent study indicated that deletion of 
p53 gene in patients with extramedullary multiple myeloma result in worse clinic 
outcome of this disease (Billecke, et al 2012). Another candidate gene is survivin, a 
member of inhibitor of apoptosis protein (IAP), represents one of the most cancer-
specific genes in the entire human genome (Reed 2002). The role of survivin was also 
analyzed in many cancer types. Sarela et al described that poor overall survival of 
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patients with colon cancer is associated with an increased survivin mRNA expression 
(Sarela, et al 2000). Similar result was also found in patients with multiple myeloma, 
researchers provided evidence that survivin directly contributed to malignant 
progression of this disease (Romagnoli, et al 2009). Overexpression of anti-apoptotic 
protein B lymphoma/leukemia-2 (Bcl-2), is common in a variety of hematopoietic 
malignancies including MM, chronic lymphocytic leukaemia (CLL), acute lymphocytic 
leukaemia (ALL) and acute myeloid leukaemia (AML). Deregulation of different 
members of the BCL-2 family was also studied in several cancers, in particular in 
hematopoietic malignancies (Kitada, et al 2002). Taken together, understanding 
apoptosis resistance in cancer will provide a basis for better anti-cancer treatment. 
 
1.2.2 Extrinsic apoptosis signaling 
Apoptosis can be triggered mainly through two pathways, the extrinsic pathway also 
known as death receptor-mediated pathway and the intrinsic pathway also known as 
mitochondria-mediated pathway (Fadeel and Orrenius 2005). The extrinsic pathway is 
initiated by a series of sensors known as death receptors and of them six receptors are 
described including: TNF receptor 1, Fas, DR3, TNF-related apoptosis inducing ligand 
receptor 1 (TRAIL-R1), TRAIL-R2 and DR6 (Suliman, et al 2001). Death receptors 
bind to their specific ligands (FasR/FasL, TNFR1/TNFα, DR-4/TRAIL, DR5/TRAIL, 
DR3/Apo-3L/TWEAK). Once activated, the intracellular death receptors domain (DD) 
bind to adaptor proteins, such as Fas-associated death domain (FADD) to form the 
death-inducing signaling complex (DISC) with accumulation of pro-caspase 8 (Burz, et 
al 2009). The subsequent pathways are different in different types of cell, one is so 
called type I cell and another is type II cell. In type I cell, high level of DISC and 
activation of caspase 8 are sufficient to stimulate downstream effector caspases such as 
caspase-3 and -7, to initiate apoptosis process. In contrast, type II cells need further 
amplification via mitochondria in order to cause inevitable apoptosis (Fadeel and 
Orrenius 2005).  
 
1.2.3 Intrinsic apoptosis signaling 
The intrinsic pathway is initiated by toxic stimuli inside the cells, such as DNA damage, 
oxidative stress, hypoxia and cytotoxic compounds (Danial and Korsmeyer 2004). 
Mitochondria and associated proteins are major players in this process. There is group 
of pro-apoptotic proteins located in the mitochondrial intermembrane space which 
contribute to cell death induction, such as apoptosis inducing factor (AIF), cytochrome 
c (cyt C), second mitochondrial activator of caspases (Smac/DIABLO), Omi/HtrA2, 
and Endonuclease G (Endo G). Any change of the inner mitochondria membrane 
potential (MMP) will cause release of these pro-apoptotic proteins from mitochondria 
to cytosol. Subsequently, cyt C stimulates apoptosome formation (a complex consist of 
apoptotic protease-activating factor [Apaf-1], dATP, cyt C and caspase 9) and caspase-
9 activation. The “initiator” caspase-9 in turn actives downstream caspase-3 and -7, 
finally resulting in cell death (Burz, et al 2009, Fadeel, et al 2008). Smac/DIABLO and 
Omi/HtrA2 can bind members of the inhibitor of apoptosis protein family (IAP), which 
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negatively control the process of caspase activation, thus amplifying the process (Cory 
and Adams 2002). 
 
1.2.4 HS-1-associated protein X-1 (HAX-1) 
HS-1 associated protein X-1 (HAX-1) was originally identified as a 35 KD protein that 
interacts with HS-1 (hematopoietic cell-specific lyn substrate-1), a substrate of Src 
family tyrosine kinases (Suzuki, et al 1997). Moreover, HAX-1 was suggested to have 
anti-apoptotic function due to its homology with the well-known anti-apoptotic protein 
Bcl-2 (Suzuki, et al 1997). Severe congenital neutropenia (SCN) or Kostmann disease 
was first described by Rolf Kostmann, a Swedish pediatrician, in his doctoral thesis 
published in 1965. These patients were characterized by a maturation arrest in the bone 
marrow and a lack of mature neutrophils in the peripheral blood (Carlsson, et al 2008). 
Subsequently, homozygous mutation of HAX1 gene was found in patients with 
kostmann disease, including three patients belonging to the original Swedish kindred 
described by doctor Kostmann, and HAX-1 was shown to play a role in protecting 
myeloid stem cells in the bone marrow from apoptosis (Klein, et al 2007). Moreover, 
HAX-1 tissue expression is ubiquitous (Carlsson, et al 2008, Suzuki, et al 1997) and 
several different splice variants have been identified (Lees, et al 2008).  
 
The localization of HAX-1 may vary in different cell types, and it has been reported to 
localize in mitochondria, in the cytosol, as well as on the endoplasmic reticulum 
(Fadeel and Grzybowska 2009). Furthermore, one recent publication indicated that 
HAX-1 is a nucleocytoplasmatic shutting protein with a possible role of mRNA 
processing (Grzybowska, et al 2013). With its varied localization, HAX-1 has been 
shown to interact with a number of cellular and viral proteins as well as mRNA, and its 
involvement in multiple signaling pathway and cellular process has also been discussed 
and addressed (Fadeel and Grzybowska 2009). Among them, numerous studies have 
concerned its role in apoptosis or interaction with apoptosis-regulatory proteins. Recent 
in vivo study supported this notion by showing that, mice that having homozygous 
deletion of HAX1 gene fail to eat and drink due to excessive apoptosis of their neurons 
in the striatum and cerebellum (Chao, et al 2008). Another study in HAX1-deficient 
mice also showed that these mice died around that age of 12 week (premature age) 
accompanied with a severe reduction of lymphocytes in spleen, thymus and bone 
marrow, further reflecting the role of HAX-1 in protecting certain cell types against 
apoptosis (Peckl-Schmid, et al 2010). Han et al reported that HAX-1 associated with 
caspase-9. Furthermore, overexpression of HAX-1 in cardiac myocytes protected them 
from apoptosis (Han, et al 2006). In addition, previous study from our laboratory found 
that HAX-1 was highly expressed in certain hematopoietic malignances, in particular in 
B lymphoma; they also noted an apparent negative correlation between HAX-1 and 
BCL-2 expression in follicular lymphoma, which might provide some hints to studies 
its anti-apoptotic role in cancer, especially in hematopoietic malignancies (Kwiecinska, 
et al 2011).  
 
In addition to its role in apoptosis discussed above, there is growing evidence showing 
that HAX-1 is involved in cell migration. HAX-1 has been shown to interact with 
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cortactin, a F-actin-associated protein, further silencing HAX-1 expression on a mouse 
embryonic fibroblast cell line NIH3T3 cells impaired its migration ability (Radhika, et 
al 2004). HAX-1 binds directly to β6 and regulates clathrin-mediated endocytosis of 
αvβ6 integrin in oral cancer, thereby regulating migration and invasion ability of oral 
cancer cells (Ramsay, et al 2007). Recent studies have shown that HAX-1 regulates 
integrin-mediated adhesion and motility of neutrophil-like cells (Cavnar, et al 2011). 
Taken together, these data suggest that HAX-1 might be important not only for cell 
survival/apoptosis but also for cell migration and, hence, for metastatic tumor 
progression, thus making HAX-1 a potentially important target for therapeutic 
intervention. 
 
1.3 PROTEASOME INHIBITION 
1.3.1 The 26S proteasome 
Continuous intracellular protein turnover is critical for the maintenance of cellular 
homeostasis, and the two major protein degradation systems within cells are: the 
lysosome system and the ubiquitin-proteasome system (Martinez-Vicente, et al 2005). 
The proteasome, often referred to the 26S proteasome, is a large multicatalytic enzyme 
complex localized in the cytosol and nucleus of all eukaryotic cells, and responsible for 
degradation of ubiquinated proteins (Adams 2004). For a protein that further to be 
recognized by the proteasome, a small peptide called ubiquitin must be first attached as 
“flags” to the protein, and this process is carried out by a cascade of enzymes (known 
as E1, E2 and E3) that active free ubiquitin and attach it to the target protein (Pickart 
2001, Wilkinson 1999). The 26S proteasome can be further divided into two sub-
complexes, a central 20S core particle (CP) associated with one or two 19S regulatory 
particle (RP) (Zwickl, et al 1999) (Figure 1). 
 
The 20S proteasome is the degradation unit and composed of four stacks of 
heptametrical subunits arranged around a central cavity. It has a barrel-like structure, 
with two outer rings containing seven different α-subunits that cap two inner rings 
containing seven different β-subunits (Groll, et al 1997). The proteolytic activity is 
located in the center chamber, and has been named as caspase-like, trypsin-like and 
chymotrypsin-like sits due to their substrate specificity and activity (Groll, et al 2001). 
Proteins are then degraded by the core particles, and afterword to generate peptides of 
3-25 amino acids length (Nussbaum, et al 1998). This process that is carried out by 
proteasome for degrading ubiquitinated proteins is specific and also highly regulated by 
19S RP, in order to prevent the erroneous degradation (D'Arcy and Linder 2012). The 
19S RP (often referred to as PA700 in mammalian cells) is composed of a lid sub-
complex and a base sub-complex. The base subunits of the 19S RP function as the 
guard of the 20S particle, to unwind the proteins and translocate them into the 20s 
particle, whereas the lid subunits are required for ubiquitin-dependent degradation 
(Glickman, et al 1998, Lander, et al 2012, Rabl, et al 2008). Thus, the 19S RP plays an 
essential role of controlling the degradation of ubiquitin-tagged proteins. 
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However, protein ubiquitination is a reversible process, in which three human 
deubiquitinases (DUBs) that are associated with 19s RP are also involved in this 
process (Fraile, et al 2012, Nath and Shadan 2009). Among them, UCHL5/Uch37 and 
USP14/Ubp16 are two DUBs belonging to cysteine protease, and the third 
RPN11/POH1 is a Zn
2+
-dependent protease (Wing 2003). The function of USP14 and 
UCHL5 is to control and make sure that substrates which contain short or non-
degradable ubiquitin chains are released from the proteasome, in order to avoid the 
accumulation of polyubiquitins (Lam, et al 1997). Therefore, functional USP14 and 
UCHL5 are also essential for proteasome-mediated degradation of proteins, while the 
lack of DUS activity may impair proteasome activity (Hanna, et al 2006).  
 
 
 
 
Figure 1. Schematic figure of 26S proteasome and inhibitory actions of proteasome 
inhibitor bortezomib and b-AP15. 
 
 
1.3.2 Proteasome as a target for cancer therapy 
The idea of targeting proteasome as a cancer therapy is apparent, since the 26S 
proteasome is involved in numerous signaling pathways including: cell differentiation, 
proliferation, cell cycling, apoptosis, gene transcription, thus any drug interfering with 
proteasome function will have pleiotropic effect (D'Arcy and Linder 2012, McCloskey, 
et al 2008). Several intracellular proteins such as p53 and IҡB, the inhibitor of nuclear 
transcriptional factor kappa B (NF-ҡB), that govern cell growth and survival are 
regulated by proteasome-mediated pathway (Adams 2004). NF-ҡB is inactivated in the 
cytoplasm under normal conditions and will become active once its binding partner, 
IҡB, is degraded by proteasome. However, constitutive NF-ҡB activity has been 
observed in a variety of tumors including MM, and this sustained activity of NF-ҡB 
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may lead to aberrant expression of target genes that promoting tumor cell proliferation 
and survival (Gilmore 2007). In addition, major tumor suppressor gene p53 as well as 
cyclin-dependent kinase inhibitors p21 and p27 can also be stabilized by inhibiting 
proteasome activity, resulting in p53-dependent apoptosis and growth arrest.(LeBlanc, 
et al 2002, Williams and McConkey 2003). More evidence was shown that the level of 
several pro-apoptotic proteins such as Bid, Bax were increased after proteasome 
inhibition, thus lead to augmentation of apoptotic signaling (Zhu, et al 2005). Other 
potential effects related to proteasome inhibition were also testified in numerous studies. 
ER stress, after proteasome inhibition was first revealed due to the intimate association 
between the ER and proteasome (Fribley, et al 2004). Moreover, rapid production of 
reactive oxygen species (ROS) was also seen after blocking proteasome degradation 
pathway (Ling, et al 2003). Taken the evidence above, the proteasome emerges as an 
obvious target for cancer therapy. 
 
The proteasome inhibitor bortezomib (PS-341, NSC 681239, velcade
®
), a modified 
dipeptide boronic acid, is a selective 20S proteasome inhibitor (Figure 1). It was 
approved by the US Food and Drug Administration (FDA) for treatment of refractory 
MM in 2003, and in 2005 it was introduced to relapse MM due to its prominent anti-
cancer function (Richardson and Anderson 2003, Richardson, et al 2003). Bortezmib 
triggers apoptosis of MM by blocking NF-ҡB pathway, and also an interfering 
production of IL-6 which is critical for MM growth (Hideshima, et al 2005). 
Bortezomib also induces the process of caspase activity and followed by PARP 
cleavage (Hideshima, et al 2003a). An in vivo study also indicated that bortezomib 
impairs human MM cells growth and angiogenesis associated with the tumor (LeBlanc, 
et al 2002). In addition to its direct cytotoxic effects, bortezomib sensitizes MM cells to 
DNA-damaging therapeutic drugs, and also inhibit DNA repair (Hideshima, et al 
2003b, Mitsiades, et al 2003). Stromal cells in the bone marrow have been thought to 
contribute to drug resistance, and bortezomib was shown to interfere with MM and 
stromal cell interaction by decreasing adhesion molecules of MM cells and also 
cytokine secretion by stromal cells (Hideshima, et al 2001). Another interesting study 
showed that bortezomib could sensitize tumor cells to NK cell-mediated lysis through 
TRAIL and/or Fas/Fas ligand pathway (Lundqvist, et al 2006).  
 
Besides the success for treatment of MM, bortezomib also became an emerging agent 
for mantle cell lymphoma (Camara-Clayette, et al 2012). In addition, its therapeutic 
efficacy has been shown in some solid tumors including non-small lung (Aghajanian, et 
al 2002) and androgen-independent prostate carcinoma (Papandreou, et al 2004), even 
though the anti-tumor effects of proteasome inhibitor on solid tumors are less 
pronounced than MM and mantle cell lymphoma.  
 
Based on the remarkable success of bortezomib, the next generation of proteasome 
inhibitor has also entered clinical trials, including carfilzomib, which has activity 
against bortezomib-resistant tumor cells (Kuhn, et al 2007), and ONX-0912 which can 
be administrated orally instead of intravenously (Chauhan, et al 2010). b-AP15 (3,5-
bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one) was initially identified 
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as a small molecule that induces p53-independent apoptosis (Erdal, et al 2005) with a 
gene expression pattern characteristic of several known proteasome inhibitors (D'Arcy, 
et al 2011). Further studies showed that b-AP15 blocks the deubiquitinase (DUB) 
activity of the 19S RP without inhibiting the proteolytic activities of the 20S CP (for an 
excellent review, see D’Arcy and Linder, 2012) (Figure 1). Interestingly, b-AP15 is 
capable of induction of apoptosis irrespective of p53 status and overexpression of the 
anti-apoptotic protein Bcl-2 (D'Arcy, et al 2011). Elevated expression of Bcl-2 and lack 
of p53 contribute to resistance against bortezomib (Ling, et al 2010, Paoluzzi, et al 
2008). DUB inhibitors may thus offer novel therapeutic approaches. Moreover, novel 
techniques for producing natural proteasome inhibitor, which could serve better 
therapeutic effects but less side effects are being explored (Stein and Groll 2013).  
 
1.3.3 Adverse effects of proteasome inhibition 
As one coin has two sides, the adverse effects of proteasome inhibitor were also 
pointed out along with its success. The most common side effect of bortezomib 
reported by hematologists, during clinical treatment, includes gastrointestinal 
symptoms, fatigue, thrombocytopenia, sensory neuropathy, vomiting, and anoxia 
(Jagannath, et al 2004, Richardson, et al 2003, Richardson, et al 2005), and among 
them peripheral neuropathy is the most severe toxicity of bortezomib therapy for 
advanced MM patients (Cavo 2007). Moreover, basic research also indicated its 
cytotoxic effects on immune system. Recent studies have demonstrated that bortezomib 
induces apoptosis in immune-competent cells, such as T cells and DCs, and also 
adversely affects the biological function of these cells (Berges, et al 2008, Blanco, et al 
2006, Straube, et al 2007). One in vivo study also indicated that bortezomib affected 
priming process of T cells, resulting in increased susceptibility of mice to virus 
infection (Basler, et al 2009). Supportively, it has been reported that bortezomib-treated 
MM patients are sensitive to viral infection due to a toxic effect on NK cells and CD8+ 
T cells (Kim, et al 2008). Taken together, it might be true that MM patients under this 
treatment could have an impaired immunesurveilince system, which will in the end 
affect the outcome of this disease. Therefore, more studies are needed to better 
understand the mechanism of proteasome inhibition, to overcome its side effects and 
improve its clinical effect. 
 
1.4 NATURAL KILLER CELLS 
1.4.1 NK cell function 
Natural killer cells (or NK cells) are large granular lymphocytes, principally found in 
the peripheral blood and lymphoid tissues (Caligiuri 2008). They were named “natural 
killer” because of the initial notion that unlike T cells, they do not require activation in 
order to kill cells that are missing “self” markers of MHC class I (Smyth, et al 2005). 
The discovery of NK cells dates back to the early 1970s by doctoral student Rolf 
Kiessling from Karolinska Institutet (Kiessling, et al 1975), in the mouse, and later by 
Hugh Pross and doctoral student Mikael Jondal, from Karolinska Institutet, in human 
(Jondal and Pross 1975, Pross and Jondal 1975). NK cells can be defined as a 
population of CD56(+)CD3(-) cells by flow cytometry. Further studies separated NK 
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cells into two groups consisting of CD56
dim
 NK cells which with potent cytotoxic 
effects towards target cells and CD56 
bright
 NK cells with the function of cytokine 
secretion (Caligiuri 2008). Moreover, NK cells as innate lymphoid cells, are critical 
effector cells of innate immunity and also have a role in tissue modeling (Spits, et al 
2013). 
 
NK cells serve a very important role in host defense to virus, bacteria, certain parasites 
and tumors. IL-2-activated NK cells have been used in the clinical trials for treatment 
of solid primary or metastasized cancer (Rosenberg, et al 1993). NK deficiency in 
humans lead to severe fatal infection during childhood, further supporting this notion 
(Orange 2006). NK cells mainly use cytolytic granules (perforin/granzyme) and death 
receptor (eg. Fas, TRAIL)-mediated pathways to process their effector functions 
(Orange 2006). Furthermore, NK cells can also secret cytokines and chemokines that 
could influence the host immune response to kill target cells, or interact with adaptive 
immunity by stimulating DCs and promoting T-cell responses, as well as activate 
macrophage-mediated killing of obligate intracellular pathogens (Caligiuri 2008, 
Filipe-Santos, et al 2006). Interferon gamma (INF-γ) is considered as the prototypic 
cytokine secreted by NK cells, which has anti-proliferative effect on virus-infected and 
transformed cells (Maher, et al 2007), as well as the function of shaping Th1 responses 
(Mocikat, et al 2003).  
 
1.4.2 NK cell killing of target cells 
The direct killing of cancer or pathogen-infected cells occurs mainly through 
perforin/granzyme granule-mediated exocytosis or via signaling through death receptor 
family members (Smyth, et al 2005) (Figure 2).  
 
NK cells secret cytotoxic granules upon interaction with target cells, and the cell death 
mediated by the exocytosis pathway is fast, powerful and multi-faceted, within minutes, 
therefore limiting pathogen replication and spread (Smyth, et al 2005). The cytotoxic 
granules secreted by NK cells are composed of complex organelles with degradative 
functions of typical lysosome. Among them, major granular proteins include perforin, a 
member of disrupting protein, and granzymes, a family of structural similarity with 
serine protease with biodegradation ability (Smyth, et al 2005). Most researchers 
believe that perforin and granzymes work as partners, with perforin making 
transmembrane pores on the target cells which facilitates the uptake of granzymes into 
cells. Further studies about perforin mutation in a severe, inherited human disorder of 
immue dysregulation known as familial haemophagocytic lymphohistocytosis (FHL), 
highlighted the importance of perforin in NK cell granule-mediated cytotoxicity (Stepp, 
et al 1999). However, other notions also indicated that the uptake of granzymes does 
not require perforin and is mediated by receptor-mediated endocytosis, in particular, 
mannose 6-phosphate receptor (MPR) can act as mediators for granzymes uptake 
(Motyka, et al 2000). Five granzymes (A, B, H, K and M) have been found in human, 
and among them granzyme B was considered to play a critical role in trigging cell 
death either directly, or via the activation of cellular caspases (Trapani, et al 2000). 
Once in the cytosol, granzyme B can either directly active caspases and initiate the 
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caspase cascade to DNA fragmentation and apoptosis, or trigger cell death via 
activation of mitochondria (intrinsic) pathway, through cleavage of Bid (Lord, et al 
2003). Thus, granule-mediated exocytosis pathway acts as a main player to initiate cell 
death of offending cells (Figure 2). 
 
TNF-related apoptosis inducing ligand (TRAIL) or Apol2L belongs to the death 
receptor family, it has high homology to other members of TNF family and close 
relation to Fas/Apol-1 ligand (Wiley, et al 1995). TRAIL is mostly expressed in T cells 
and NK cells of immune system, where it plays roles of killing transformed cells 
(Janssen, et al 2005, Smyth, et al 2003). TRAIL can band to its cell-bound receptors: 
two apoptosis-inducing receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), another 
two receptors are TRAIL-R3 (LIT, DcR1) and TRAIL-R4 (TRUNDD, DcR2), also 
called decoy receptors which are incapable to transmit apoptotic signaling, as well as 
the fifth soluble receptor osteoprotegerin (OPG) (Falschlehner, et al 2007). Binding of 
TRAIL to DR1 or DR2 results in apoptosis via extrinsic pathway (Figure 2). Previous 
studies supported a critical role of TRAIL in NK cell-mediated immunosurveillance 
against tumors (Falschlehner, et al 2009). In addition, normal cells express decoy 
receptors which could protect them from TRAIL-induced apoptosis (Pan, et al 1997), 
making TRAIL an excellent target for cancer therapy. Studies have reflected that 
administration of rhTRAIL and agonistic antibodies induce increased apoptosis in 
many cancer cell lines (Oldenhuis, et al 2008). Moreover, the combination of rhTRAIL 
with various antitumor agents gained more interest, in particular in combination with 
proteasome inhibitors. Thus, the combination of rhTRAIL and bortezomib has been 
studied in many cell lines, and also showed a better efficacy than single treatment 
(Hellwig and Rehm 2012). 
 
Another member of death receptor family is FasL, Fas/FasL-mediated apoptotic 
signaling pathway also plays essential role during immunosurveillance (Villa-Morales 
and Fernández-Piqueras 2012) (Figure 2). Moreover, Fas and FasL gene were defined 
as tumor suppressor genes (Muschen, et al 2000). Fas is not constitutively expressed on 
tumor cells, however, INF-γ secreted by NK cells can up-regulate Fas expression on 
tumor cells, thus triggers Fas-dependent killing activity (Screpanti, et al 2001). 
Administration of recombinant IL-18 or IL-2 suppresses tumor metastases in mice 
mainly due to Fas/FasL-mediated killing by NK cells (Hashimoto, et al 1999). 
Collectively, studies have demonstrated the fundamental role of NK cell-mediated 
killing activity in immune system against tumors.  
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Figure 2. Two pathways of NK cell-mediated killing: granule exocytosis pathway and 
death receptor mediated pathway. 
 
 
 
1.4.3 Inhibitory receptors and activating receptors 
The function of NK cells also depends on the balance between inhibitory receptors and 
activating receptors expressed on them. Three inhibitory receptors have been found and 
characterized: the killer cell Ig-like receptors (KIR) in humans, the Ly49 lectin-like 
receptors in mice and CD94/NKG2A lectin-like receptors shared by human and mice, 
they all signal through intracellular immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs), which located in the cytoplasmic tail of these receptors (Pegram, et al 2011, 
Smyth, et al 2005). Target cells that express normal level of MHC class I molecules or 
MHC class I-related molecules can be protected once NK cell inhibitory receptors bind 
to these molecules, thus NK cell effector function (cytotoxicity and cytokine production) 
will be further blocked (Smyth, et al 2005). Studies also indicated that inhibitory signal 
can influence both NK cell-mediated cytotoxicity and adhesion ability of NK cells to 
target cells (Bryceson, et al 2009).  
 
In contrast, NK cell activating receptors currently refer to the receptors that induce 
release of cytolytic granules and trigger cytokine production. Characterized activating 
receptors on NK cells include the natural cytotoxicity receptors (NCRs) (e.g. NKp30, 
NKp44 and NKp46), NKG2D, NKRP1, CD16 and activating KIRs, moreover, other 
receptors such as LFA-1, DNAM and members of the CD2 family are also involved in 
trigging NK cell activity. (Kirwan and Burshtyn 2007).  
 
NCRs consist of NKp30, NKp44 and NKp46 as described above. Among them, the 
NKp30 and NKp46 receptors are expressed on both resting and activated NK cells, 
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whereas NKp44 receptor is expressed on activated NK cells only (Bottino, et al 2000). 
Activation of all NCRs results in direct killing of target cells. The NKp46, studied in 
the current thesis, is considered as a major player for NK cell-mediated killing function 
(Mandelboim and Porgador 2001). NKp46 is a member of immunoglobulin 
superfamily, characterized by two extracellular C2-type Ig-like domains. The function 
of NKp46 was shown to bind putative ligands of tumor cells, then lyse the target cells, 
conversely, block of NKp46-mediated pathway using NKp46 mAb prevents the killing 
of large panel of tumor cells (Sivori, et al 1999). It was also reported that NKp46 
interacts with virus hemagglutinins (HAs), therefore leading to the lysis of virus-
infected cells (Mandelboim and Porgador 2001). Other activating receptors, such as 
NKG2D, which is expressed on NK cells, γδ+ T cells, CD8+ αβ T cells and activated 
macrophages, also play a fundamental role of defending infected and transformed cells 
in both innate and adaptive immune responds (Diefenbach, et al 2000, Jamieson, et al 
2002). The NKG2D molecule recognizes several different ligand, and has been 
reported to have a role of stimulating immunity against tumors, as well as the induction 
of CTL, Th1 and Th2 responses (Diefenbach, et al 2001, Westwood, et al 2004).  
 
Taken together, a functional immunity is considered to be a powerful barrier against 
cancer development, and it is very important to maintain its function during cancer 
therapy. 
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2  AIM OF THE STUDY 
 
The overall aim of this Ph.D. project is to uncover potential roles of proteasome 
inhibition in the regulation of natural killer (NK) cell function and multiple myeloma 
(MM) cell apoptosis, We hope that these studies will enable the design of an optimized 
proteasome inhibition-based treatment protocol for multiple myeloma patients. The 
specific aims are: 
 
I, To investigate a possible role of proteasome inhibition by inhibitors such as 
bortezomib in the regulation of NK cell survival and the underlying mechanisms 
related to treatment in vitro. 
 
II, To explore potential effects of proteasome inhibition by bortezomib on death 
receptor-mediated functions, including TNF-related apoptosis-inducing ligand (TRAIL) 
and Fas ligand (FasL)-associated cytotoxicity by NK cells.  
 
III, To analyze the potential pro-apoptotic effects of the novel proteasome inhibitor b-
AP15 on human MM cells and NK cells. 
 
IV, To study the putative regulatory function of HS1-associated X1 (HAX-1) on MM 
cells, including sensitization of MM cells to apoptosis induced by NK cells and 
proteasome inhibitors, as well as regulation of cell migration. 
  
 
  15 
 
 
3 MATERIALS AND METHODS 
Detailed description of the techniques, materials and methods used in our studies can be 
found in the publications and manuscripts included in the current thesis. The sections 
below provide an overview of the methods. 
 
3.1 CELL CULTURE 
3.1.1 Cancer cell lines 
K562 cells 
K562 cell line is the first human immortalized myelogenous leukemia line to be 
established, the line was derived from a 53 year old female CML patient in blast crisis 
(Lozzio and Lozzio 1975). K562 cell line was obtained from the American Tissue 
Culture Collection (ATCC) and maintained in RPMI-1640 medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich) plus penicillin (10 
U/mL) and streptomycin (10 U/mL), in a humidified incubator at 37
o
C and 5% CO2. 
Cells were kept in a logarithmic growth phase for all experiments (paper I and II). 
 
P815 cells 
FcγR+P815 is a murine mastocytoma cell line provided by Dr Yenan Bryceson, 
Karolinska Institutet. Cells were maintained in RPMI-1640 medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich) plus penicillin (10 
U/mL) and streptomycin (10 U/mL), in a humidified incubator at 37
o
C and 5% CO2. 
Cells were kept in a logarithmic growth phase for all experiments. FcγR+P815 cells 
were pre-incubated with NKp46 antibody (2.5μg/mL) for 30 min, before applying them 
to redirected cytotoxicity assay (paper I).  
 
RPMI8226 cells and U266 cells 
RPMI8226 cells were derived from the peripheral blood of a 61 years old male with 
multiple myeloma (Matsuoka, et al 1967). U266 cells were derived from peripheral 
blood of a 53 years old male with myeloma (Nilsson, et al 1970). Both cell lines were 
obtained from the ATCC and maintained in RPMI-1640 medium supplemented with 
15% (U266) or 10% (RPMI8226) heat-inactivated fetal bovine serum (FBS) (Sigma-
Aldrich) plus penicillin (10 U/mL) and streptomycin (10 U/mL). Cells were kept in a 
logarithmic growth phase for all experiments (paper II, III and IV). 
 
Jurkat cells 
The human Jurkat cells were established from the peripheral blood of 14 years old boy 
with T cell leukemia (Schneider, et al 1977). This cell line was maintained in RPMI-
1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Sigma-Aldrich) plus penicillin (10 U/mL) and streptomycin (10 U/mL), in a 
humidified incubator at 37
o
C and 5% CO2. Cells were kept in a logarithmic growth 
phase for all experiments (paper IV). 
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3.1.2 LAK and NK cells 
Human peripheral blood mononuclear cells (PBMCs) from adult blood donors 
(Karolinska University Hospital, Stockholm, Sweden) were separated by Ficoll-Paque 
gradient centrifugation (Amersham Biosciences AB, Uppsala, Sweden). Peripheral 
blood lymphocytes (PBLs) were generated by culturing PBMCs (5.0×10
6
/mL) for 45 
min, followed by collection of non-adherent cells (PBLs) and re-suspension in cell 
culture medium at 1.0×10
6
/mL. To generate lymphokine-activated killer (LAK) cells, 
PBLs were cultured in presence of 400 U/ml of IL-2 (R&D Sys- tems, Abingdon, UK) 
for 48 h (paper II). 
 
We applied two kinds of methods to isolate NK cells from PBMCs. In paper I, II and 
IV, NK cells were isolated from PBMCs using the RosetteSep NK cell purification kit 
(Stemcell Technologies, Vancouver, Canada) and following the method described 
previously (Marcenaro, et al 2006), with minor modifications. Briefly, 20×10
6
 PBMCs 
were mixed with autologous red blood cells (RBCs) with an RBC/PBMC ratio of 40:1, 
suspended in 1 ml complete RPMI-1640 medium and incubated with 50 μL RosetteSep 
cocktail for 20 min at RT. Then, the sample was diluted 2 times with complete medium 
before loading on Ficoll-Hypaque for separation. After centrifugation, NK cells were 
recovered from the interface. In paper III, NK cells were isolated from NK Cell 
Isolation Kit (Miltenyi Biotec Norden AB, Lund, Sweden), PBMCs were suspended in 
PBS buffer containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA. Then, NK 
Cell Biotin-Antibody Cocktail was added, and samples were refrigerated for 10 min 
followed by centrifugation at 300xg for 10 min, whereupon the cell pellet was re-
suspended in NK Cell Microbead Cocktail, and refrigerated for 15 min. Cells were re-
suspended in buffer and centrifuged at 300xg for 10 min, then re-suspended again in 
buffer and applied onto the magnetic column, to enrich for NK cells. Purity of NK cells 
(CD56
+
 CD3
-
) from the two methods was approx. 90%, as determined by staining with 
CD56 and CD3 mAbs.  
 
3.1.3 Co-culture system 
Standard (4 h) chromium 51 (
51
Cr)-release assay (Paper I, II and IV) or prolonged (12 h) 
51
Cr-release assay (Paper II) were performed using protocol described previously 
(Zheng, et al 2002), to analyze cytotoxicity of resting NK (rNK) cells (paper I) , LAK 
cells (paper II) and PBLs (paper IV)to target cells. Briefly, effector cells were incubated 
with 
51
Cr (Amersham Biosciences, Uppsala, Sweden) labeled target cells (K562 and 
Fc R
+
 P815 for paper I), (K562, RPMI8226 and U266 for paper II) and (RPMI8226 
and U266 for paper IV) in triplicates at various effector to target (E/T) ratios. After 4 h 
or 12 h incubation at 37
o
C, 100 µl of cell-free supernatants were collected and the 
amount of 
51
Cr released into the supernatants was measured using an automatic gamma 
counter (Wallac, Upplands Väsby, Sweden). Specific lysis was calculated by the 
method described previously (Zheng, et al 2002). 
 
CD107a surface translocation assay was performed to quantify NK cell degranulation 
activity following the method published previously with minor modiﬁcations 
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(Bryceson, et al 2007). LAK (effector) cells and K562 (target) cells were seeded at an 
effector to target (E:T) ratio of 1:1 in 200μL complete medium in a 96-well plate in 
duplicate, and then the cells were centrifuged at a speed of 300 rpm for 3 min, FITC-
conjugated CD107a (BD Pharmingen) was added into each well, and cells were 
incubated at 37
o
C for 2 h. Then, cells were harvested, washed with cold PBS and 
stained with PE-conjugated anti-human CD3 and PECy5-conjugated anti-human CD56 
mAbs (BD Pharmingen) as described above. CD107a
+
CD56
+
CD3
−
 cells were deﬁned 
as degranulated NK cells and quantiﬁed by using the CELLQUEST software (Becton 
Dick- inson) (paper II).  
 
To deliver endogenous granzyme B to RPMI8226 cells, purified NK cells were isolated 
from PBMCs using the RosetteSep NK cell purification kit (Stemcell Tech-nologies, 
Vancouver, Canada) as described above, NK cells from healthy donor were seeded 
with RPMI8226 cells at effector to target (E:T) ratio of 2:1, after incubation for 4 h, 
cells were collected and prepared for western blot analysis (paper IV). 
 
3.2 FLOW CYTOMETRY 
3.2.1 Phosphatidylserine exposure 
Plasma membrane exposure of phosphatidylserine (PS) was quantified by dual labeling 
with Annexin V-Fluos (AV) (Roche Diagnostics GmbH, Mannheim, Germany) and 
propidium iodide (PI) (Sigma Aldrich) according to the protocol provided by the 
manufacturer. Cells were then collected and washed twice with cold PBS, re-suspended 
in 100 µL of binding buffer containing AV and PI, followed by incubation for 15 min 
at RT. Then, 400 µL of incubation buffer was added, and cells were analyzed by flow 
cytometry within 30 min on a FACS Calibur (Becton Dickinson, San Jose, CA). 
AV
+
PI
+ 
cells and AV
+
PI
-
 cells were defined as apoptotic cells (paper I, II, III and IV). 
 
3.2.2 Cell surface and intracellular protein detection 
For surface staining, cells were first incubated with 10% FCS-PBS buffer for 15 min at 
RT to block non-specific binding of antibodies to Fc receptors. The cells were then 
stained with fluorescence labeled antibodies in 10% FBS-PBS buffer for 30 min at 4°C 
(paper I, II, III, and IV). Detection of intracellular protein expression was performed by 
using the Intrastain Kit (DAKO, Glostrup, Denmark) according to instructions provided 
by the manufacturer. Briefly, NK cell surface marker (CD56) was stained first as 
described above and cells were then fixed using reagent A for 15 min at RT. After 
washing, cells were re-suspended in reagent B for cell membrane permeabilization, and 
specific antibodies or corresponding isotype control mAb was added and cells were 
incubated for 15 min at RT (paper I and II). Finally, cells were washed with PBS and 
re-suspended in 400 µl PBS prior to analysis by flow cytometry. The collected data 
were analyzed using CELLQUEST software (Becton Dickinson). 
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3.3 CASPASE-3 ACTIVITY  
Caspase activation was detected as previously described (Fadeel, et al 1998). Briefly, 
cell lysates were combined with the fluorogenic substrate, DEVD-AMC (Sigma) in a 
reaction buffer (20 mM HEPES, pH=7.5, 10% glycerol, and 10mM dithiothreitol). 
Real-time measurements of enzyme-catalyzed release of AMC were obtained using a 
Tecan Infinite F200 plate reader (Tecan Group Ltd, Männedorf, Switzerland). 
Fluorescence values were converted to pmol and the maximum rate of AMC release 
(pmol/min) was estimated for each sample. To assess the role of caspase activation, 
zVAD-fmk (Sigma) was applied as indicated (paper I and III). 
 
3.4 MITOCHONDRIAL MEMBRANE POTENTIAL 
Functional mitochondria were labeled by Mitotracker Red CMXRos (Mitotracker Red) 
(Molecular Probes, Eugene, OR) as described previously (Jayaraman 2005), with minor 
modifications. In brief, a total of 1.0x10
6
 cells were pelleted and suspended in 1 ml of 
pre-warmed complete medium with a final concentration of 125 nM Mitotracker Red 
for 35 min at 37
o
C. Excess dye was removed with two washes in pre-warmed complete 
medium at 37
o
C, and finally the labeled cells were re-suspended in PBS for 
mitochondrial membrane potential (MMP) measurement. Mitotracker Red fluorescence 
was detected using a FACS Calibur (Becton Dickinson) (paper I). 
 
3.5 REAL-TIME POLYMERASE CHAIN REACTION 
For real-time polymerase chain reaction (PCR), RNA was extracted from cells using 
RNase Mini Kit (Qiagen, Hilden, Germany). One  microgram of RNA was then treated 
with DNase I using a DNA-free kit (Ambion, Austin, TX) according to the 
manufacturer’s protocol, and cDNA was synthesized using the SuperScript ﬁrst strand 
synthesis system (Invitrogen,  Carlsbad, CA) with random hexamers. cDNA quantity 
was measured using real-time PCR with the ABI PRISM 7000 sequence detector 
system and ﬂuorescence-based SYBR-green technology (Applied Biosystems, 
Warrington, UK). PCR was performed in a ﬁnal volume of 25 μL, consisting of diluted 
cDNA sample plus 1×SYBR-green PCR Master Mix (Applied Biosystems). Primer 
sequences were designed according to a previous publication (Morissette, et al 2008). 
All samples were analyzed in duplicate (two independent experiments). The ratio of 
mRNA expression/18S rRNA expression for each sample was determined to represent 
the mRNA expression level (paper II). 
 
3.6 SMALL INTERFERING RNA (SIRNA) DELIVERY 
We applied the AMAXA Nucleofector System (Lonza Cologne AG, Germany) to 
transfect cells with targeted small interfering RNA (siRNA) and a matched control 
siRNA. Cells were re-suspended in fresh medium in a concentration of 0.5x10
6
/mL the 
day before use. After determining cell density, we centrifuged the required number of 
cells at 90xg for 10 min, then removed the supernatant completely and re-suspended 
the cell pellet gently with 100 µl Nucleofector reagent per sample. Cells were 
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electrophoresed using Nucleofector Program X-005 per million cells, and cells were 
incubated for 24 hours to have efficient knockdown (paper IV).  
 
3.7 WESTERN BLOT 
To obtain cell lysates, cells were lysed on ice for 30 min in RIPA buffer (50 mM Tris, 
PH8.0, 150 mM Nacl, 10% glycerol, 1% NP-40, 0.5% deoxycholate) supplemented 
with protease inhibitors. Protein concentration was measured using BCA
TM
 Protein 
Assay (Pierce Biotechnology Inc., Rockford, IL). Fifty μg of protein were loaded into a 
Nu-PAGE 4-12% Bis-Tris Gel (Invitrogen) and then transferred onto PVDF 
membranes. Following probing with the indicated primary antibodies the relevant 
secondary antibody (DAKOCytomation, Glostrup), the protein bands were visualized 
by enhanced chemiluminescence (BioRad Laboratories). The films were scanned using 
the Epson Perfection 4490 Scanner (EPSON Europe B.V, Sollentuna, Sweden) (paper 
III and IV). 
 
3.8 DELIVERY OF RECOMBINANT GRANZYME B 
To delivery recombinant granzyme B, cells (2x10
6
) were permeabilized using 100 µl 
permeabilization buffer (containing 150 mM KCl, 1 mM MgCl2, 10 mM Tris-x-100) 
with 10 µl 0.01% digitonin for 5 min, then 2 µl recombinant granzyme B (stock 
solution 0.2 μg/μl) were added and cells were incubated for 1 h (paper IV). 
 
3.9 CELL MIGRATION ASSAY 
To monitor the in vitro migration of cells, we utilized a 24-well Transwell system with 
polycarbonate membranes of 8 mm pore size (Corning Costar, Cambridge, MA). The 
membranes were pre-coated with 20 µg/ml fibronectin (R&D System) at 37°C for 1h, 
followed by blocking of the membranes with 0.1% BSA PBS at 37°C for another 30 
min. Cells were re-suspended at 2.5x10
6
/ml in serum-free complete RPMI1640 
medium, and were seeded onto the upper-side chamber (100 µl/well), 0.6ml of the 
same medium supplied with specific chemoattractant was added to the lower chamber. 
The cells were allowed to migrate overnight, and cells that migrated into the lower 
chamber were collected and counted using a Countess® Automated Cell Counter 
(Invitrogen) (paper IV). 
 
3.10 IN SILICO ANALYSIS OF MICROARRAY DATA 
Global gene expression profiling has become a powerful tool for exploring the 
underlying pathogenesis and biology of human cancer for many years (Kwiecinska, et 
al 2011). Expression of indicated mRNA in different cancer types was assessed using 
the In Silico Transcriptomics (IST) database, an online resource that contains data from 
9.783 Affymetrix gene expression analyses of 43 normal tissues, 68 cancer types and 
64 other diseases (Kilpinen, et al 2008) (paper IV).  
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4 RESULTS 
4.1 PAPER I: PROTEASOME INHIBITION INDUCES APOPTOSIS IN 
PRIMARY HUMAN NK CELLS AND SUPRESSES NKP46-MEDIATED 
CYTOTOXICITY 
 
In this study, we investigated the effects of proteasome inhibitor bortezomib on natural 
killer (NK) cell survival and function. 
 
Cytotoxic effects of bortezomib on NK cells were evaluated in highly purified resting 
NK (rNK) in the presence of bortezomib for 12 and 24 h. We found that bortezomib 
markedly induced apoptosis in rNK cells in a dose- and time-dependent manner. 
Furthermore, we asked the underlying mechanism of apoptosis induced by bortezomib. 
Our results demonstrated that GSH, a potent ROS scavenger, markedly abolished 
apoptosis induced by bortezomib at 4.7 ng/ml for 24 h. However, blocking caspase 
activation by zVAD-fmk, a pan-caspase inhibitor, did not effectively block total 
apoptosis in rNK cells induced by bortezomib, indicating that ROS generation 
contributes to apoptosis in rNK cells induced by bortezomib at the doses tested. To 
obtain more information on the potential mechanisms involved in bortezomib-induced 
apoptosis of rNK cells, we evaluated the role of mitochondria, which plays pivotal roles 
in the process of apoptosis, in the bortezomib-induced apoptosis in rNK cells. 
Mitochondrial membrane potential (MMP) of rNK cells cultured with bortezomib for 
12 or 24 h was measured. Our data has shown that bortezomib markedly induced a loss 
of Mitotracker Red fluorescence intensity in rNK cells in a dose-dependent manner, 
and GSH partially and significantly prevented the loss of MMP induced by bortezomib, 
further indicated bortezomib induced apoptosis of rNK cells is ROS-dependent. 
 
Next, we examined putative effects of proteasome inhibition on NK cell activation 
receptors (NKp30, NKp46, NKG2D and DNAM-1). Particular NKp46 expression in 
rNK cells was significantly reduced upon treatment with bortezomib in a time- and 
dose-dependent manner, but not expression of DNAM-1, NKG2D and NKp30, or 
perforin expression after bortezomib treatment. Since NF-κB is one of the main targets 
of proteasome inhibition (Adams 2004), we further tested NKp46 expression on rNK 
cells after blocking of NF-κB activity by a NF-κB blocker Bay 11-7082, and found that 
blocking of NF-κB activity induced significant loss of NKp46 expression on rNK cells, 
indicating that the bortezomib-induced decrease in NKp46 expression may be, at least 
in part, attributable to the known inhibitory effects of this agent on NF-κB function. 
 
To investigate the functional consequence of decreased NKp46 expression on rNK cells 
following bortezomib treatment, we employed a redirected NK cell cytotoxicity assay, 
using Fc R
+
 P815 as target cells, in presence of anti-NKp46 antibody. We found that 
the lysis of Fc R
+
 P815 cells by the rNK cells exposed to a low dose of bortezomib (4.7 
ng/mL) for 12 h was significantly decreased. Interestingly, blocking of NF-κB 
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activation by Bay 11-7082 for 12 h substantially inhibited rNK cell-mediated lysis of 
Fc R
+
 P815 cells in the presence of anti-NKp46 antibody. These results further support 
the role of NF-κB in the regulation of bortezomib-induced decrease of NKp46 
expression. 
 
Our findings demonstrated that bortezomib induces rNK cell apoptosis in a time- and 
dose-dependent manner, and reduces NKp46 receptor expression as well as NK cell 
cytotoxicity mediated through the NKp46 activation pathway. These in vitro results 
caution that bortezomib may disrupt NK cell-dependent immunosurveillance in patients 
treated with this drug. 
 
 
4.2 PAPER II: THE PROTEASOME INHIBITOR BORTEZOMIB DISRUPTS 
TRAIL EXPRESSION AND NK CELL KILLING OF TRAIL RECEPTOR-
POSITIVE MULTIPLE MYELOMA CELLS 
 
Based on the findings explored in paper I, we want to further evaluate the regulatory 
role of bortezomib in TNF-related apoptosis inducing ligand (TRAIL) and FasL of NK 
cells. 
 
The dosages and time point of bortezomib treatment applied in this study were nontoxic 
to multiple myeloma cell line RPMI8226 and U266. However, we found that TRAIL 
expression (both protein level and mRNA level) of IL-2 activated NK cells was 
decreased in a dose-dependent manner, as determined by ﬂow cytometry, but no 
increase in apoptosis was detected in IL-2 activated NK cells under these conditions. 
NF-ҡB was shown previously to be involved in the regulation of TRAIL expression 
(Wajant 2004). We further demonstrated that Bay 11-7082 substantially decreased both 
TRAIL protein and mRNA expression, indicating the role of NF-ҡB involved in 
bortezomib-mediated down regulation of TRAIL expression. In contrast, we also 
conﬁrmed that bortezomib treatment did not affect intracellular perforin expression in 
IL-2-activated NK cells nor did the bortezomib treatment affect FasL cell surface 
expression in these cells. Therefore, bortezomib appears to selectively reduce TRAIL 
expression in activated human NK cells. 
 
As exocytosis of perforin-containing granules is a major mechanism for NK cell-
dependent cytotoxicity. To explore a potential role of bortezomib in the regulation of 
the granule-exocytosis pathway, the CD107a surface translocation assay was applied 
(Bryceson, et al 2007). Our studies showed that the percentage of degranulated NK 
cells treated by bortezomib was not signiﬁcantly different from the control (untreated) 
group. Supportively, bortezomib treatment did not affect LAK-mediated killing of 
target cells, as evidenced using the standard 4 h 
51
Cr release assay. CMA has been 
shown to reduce perforin content and to block perforin-mediated cytotoxicity in NK 
cells (Saudemont, et al 2005). Moreover, for comparison, inactivation of perforin-
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mediated cytotoxicity by CMA treatment of LAK substantially blocked the killing of 
target cells in this assay. 
 
Additionally, a modiﬁed 12 h 51Cr release assay was employed to evaluate perforin-
independent killing activity. Using this assay, we observed that bortezomib treatment of 
LAK cells signiﬁcantly reduced the percentage of lysis of RPMI8226 and U266 cells as 
compared to untreated LAK cells. To further dissect the potential mechanism 
underlying the killing defect, and to determine the role of TRAIL-dependent killing in 
this assay, we employed a speciﬁc anti-TRAIL antibody to block TRAIL-mediated 
killing pathway. Interestingly, LAK cell-mediated killing activity to RPMI8226 cells 
was impaired, but did not affect the killing of U266 cells. Moreover, RPMI8226 cells 
expressed both TRAIL receptors while U266 cell line expressed DR4 and DR5 at low 
level, indicating that TRAIL is involved in the LAK cell-mediated killing of RPMI8226 
cells.  
 
To conclude, proteasome inhibition by bortezomib disrupts TRAIL expression in 
human NK cells but does not affect Fas ligand or perforin expression. This may 
potentially hamper NK-dependent immunosurveillance against tumors in patients 
treated by this drug. 
 
 
4.3 PAPER III: PRO-APOPTOTIC EFFECTS OF THE NOVEL 
PROTEASOME INHIBITOR B-AP15 ON MULTIPLE MYELOMA CELLS 
AND NK CELLS 
 
Recent studies have shown that the small molecule b-AP15, a novel inhibitor of 
proteasome deubiquitination, displays anti-tumor activity in several pre-clinical solid 
tumor models (D'Arcy, et al 2011). Herein, we wanted to study the potential regulatory 
effects of b-AP15 on multiple myeloma cells, as well as NK cells. 
 
We first demonstrated that b-AP15 induces time- and dose-dependent apoptosis in MM 
cell lines. Moreover, accumulation of ubiquitin-conjugated proteins was evaluated by 
western blot, indicating that b-AP15-induced apoptosis in MM cells is associated with 
proteasome inhibition. Caspase-3 is a key protease in the apoptosis pathway (Andón 
and Fadeel 2012), we further monitored activation of pro-caspase-3, as well as cleavage 
of the nuclear protein, PARP, a downstream target protein of caspase-3, our results 
revealed the underlying mechanism of b-AP15-triggered apoptosis in MM cells. 
Additionally, b-AP15-induced caspase-3 activation was also quantified by DEVD-
AMC cleavage. As noted above, caspase activation seems to be involved in b-AP15-
induced apoptosis in MM cells. Interestingly, b-AP15-triggered apoptosis of MM cells 
was significantly reduced after pre-incubation with zVAD-fmk (a pan-caspase 
inhibitor), further suggesting the importance of caspase activation in b-AP15-induced 
apoptosis. 
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Next, we examined whether b-AP15 has any pro-apoptotic effects on NK cells. Highly 
Purified NK cells were then exposed to b-AP15 at indicated does- and time-point. Our 
data demonstrated that, besides its cytotoxic effects on MM cells, b-AP15 also triggers 
apoptosis in NK cells in a dose- and time-dependent manner. We also applied zVAD-
fmk to study the role of caspase in b-AP15 induced apoptosis of NK cell, our finding 
suggested that both caspase-dependent and -independent pathways are engaged in this 
process. For comparison, we employed bortezomib in this system. Importantly, 
however, the pro-apoptotic effect of b-AP15 on NK cells is much lower than that of 
bortezomib, implying that b-AP15 may have less side effects on the immune system 
than bortezomib. This suggests that b-AP15 or similar drugs might have advantages to 
bortezomib in treatment of cancer patients. 
  
Taken together, we demonstrate herein that the novel proteasome inhibitor, b-AP15 
induces caspase-dependent apoptosis of human MM cells. b-AP15 also has toxic 
effects on primary human NK cells but the effect is less pronounced when compared to 
bortezomib. Therefore, b-AP15 may provide a useful approach for the treatment of 
MM with less adverse effects on immune-competent cells.  
 
 
4.4 PAPER IV: HAX-1 REGULATES MIGRATION OF MULTIPLE 
MYELOMA CELLS 
 
Recent studies from our laboratory have shown that HAX-1 is overexpressed in certain 
hematopoietic malignancies including B lymphoma (Kwiecinska, et al 2011). We 
wanted to elucidate the potential role of HAX-1 in multiple myeloma. 
 
By studying the publically available IST database, which contains microarray data from 
close to 10.000 Affymetrix analyses of normal and disease tissues (Kilpinen, et al 
2008), we found HAX1 mRNA level was elevated in multiple myeloma samples. 
Additionally, high level of HAX-1 protein expression in the human MM cell lines 
U266 and RPMI8226 was also observed. Based on our knowledge of HAX-1 in the 
regulation of apoptosis (Jitkaew, et al 2009, Li, et al 2009), we wanted to assess the 
putative role of HAX-1 for regulation of apoptosis in MM cells. First, we efficiently 
silenced HAX-1 expression in MM cells, then, control siRNA and HAX-1 siRNA 
transfected U266 cells were exposed to either bortezomib or b-AP15 at indicated dose- 
and time-points. We found that silencing of HAX-1 expression in U266 cells did not 
affect the sensitivity of these cells to these stimuli. However, a down-regulation of 
HAX-1 expression was seen after bortezomib and b-AP15 treatment, as well as Bay11-
7082 (a NF-ҡB inhibitor) treatment, indicating that the expression of HAX-1 is subject 
to NF-кB-dependent regulation in MM cells, in line with our previous experiments 
using normal EBV-transformed B cell lines (Jitkaew, et al 2009). However, we did not 
observe the up-regulation of Bcl-2 expression after HAX-1 knockdown, as shown in 
follicular lymphoma (Kwiecinska, et al 2011).  
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In line with the previous finding that granzyme B cleaves HAX-1 (Han, et al 2010), we 
observed HAX-1 cleavage in the RPMI8226 cell line in our study upon incubation with 
recombinant granzyme B. We also found for the first time that HAX-1 is cleaved in 
target cells co-cultured with NK cells. To further assess the possible role of HAX-1 in 
the protection of MM cells against NK cell-mediated killing, we applied human 
primary PBL-mediated killing to HAX-1 siRNA or control siRNA transfected U266 or 
RPMI8226 cells. Our results showed that silencing of HAX-1 in MM cells fails to 
modulate NK cell-mediated killing of these cells. 
 
HAX-1 is a multi-functional protein (Fadeel and Grzybowska 2009), and recent 
publications also revealed its role in the regulation of cell migration (Mekkawy, et al 
2012, Ramsay, et al 2007). We used the Transwell assay to study a possible role of 
HAX-1 for the migration activity of MM cells. Our data demonstrated that inhibition of 
HAX-1 expression in the U266 cell line using specific siRNA significantly decreased 
migration ability. However, the underlying mechanisms need to be further explored in 
future studies. 
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5 DISCUSSION 
 
Multiple myeloma (MM) still remains incurable, even though the clinic outcomes of 
this disease have been greatly improved due to introduction of novel therapies (Suzuki 
2013). Among these, proteasome inhibitor-based treatment has shown success; 
however, the clinical management of this novel agent needs to be further studied, in 
order to design a more effective proteasome inhibitor-based treatment. Moreover, we 
are also aiming to explore other potential target for the treatment of myeloma.  
 
Recent studies have revealed cytotoxic effects of proteasome inhibition on immune-
component cells, including T cells and DCs (Berges, et al 2008, Straube, et al 2007). 
The studies presented in the current thesis are aimed at elucidating the potential role of 
proteasome inhibition in the regulation of NK cells. For this purpose we investigated 
the effects of this agent on NK cell survival and function. In the first paper our studies 
showed for the first time that primary human rNK cells undergo apoptosis in response 
to proteasome inhibition by bortezomib, a novel anti-cancer agent. Importantly, the 
dose selected in this study (4.7 ng/ml and 18.8 ng/ml) are below the dose range mostly 
applied in patients. As known, the most commonly used dose of bortezomib in the 
clinic is 1.3 mg/m
2
 on day 1, 4, 8 and 11 of every 21 days deﬁned as one cycle, and as a 
result the concentration of bortezomib in plasma ranges from 60 to 120 ng/ml (Utecht 
and Kolesar 2008). It is clear from others studies that both generation of ROS and 
caspase activation triggered by proteasome inhibition play a critical role in bortezomib-
induced tumor cell apoptosis (Perez-Galan, et al 2006). Interestingly, our findings 
suggest that ROS generation rather than caspase activation is a key triggering factor for 
bortezomib-induced apoptosis in rNK cells. Consistently, our results showed that GSH 
almost completely prevented the dissipation of MMP, as well as caspase activation 
induced by bortezomib. Similar effects of bortezomib on malignant NK cells have been 
reported (Shen, et al 2007). Indeed, our data indicated that bortezomib may act via 
similar mechanism(s) to trigger apoptosis toward primary resting NK cells. 
 
Another question we might ask is whether NK cell-mediated cytotoxicity is also 
influenced by proteasome inhibition. NK cell function is finely regulated by a balance 
between activating and inhibiting signaling with corresponding ligands expressed on 
the target cells (Bryceson, et al 2006).We found that bortezomib selectively down-
regulated the expression of NKp46 but not other NK receptors tested (NKp30, NKG2D 
and DNAM-1) and this effect was not attributable to the apoptosis inducing-property of 
bortezomib. Consequently, NK cell cytotoxicity to Fc R
+
 P815 cells mediated by the 
NKp46 activation pathway was impaired, and these results were in line with the 
decreased NKp46 expression observed after administration of bortezomib. Moreover, 
NF-κB was shown to play an important role in regulating the expression of NK surface 
molecules in mice (Pascal, et al 2007), as well as a main target for proteasome 
inhibition (Ciechanover 1994). Our data indeed showed the blocking effects of NF-κB 
mediated by bortezomib may be involved in the selective down-regulation of NKp46 
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expression. In addition, another novel discovery by Gur et al makes our study more 
interesting. These authors found that NKp46 recognize its ligands on human and mouse 
pancreatic beta cells, thus mediated the damage that caused by this activation and 
contributed to the development of type 1 diabetes (Gur, et al 2010). This might suggest 
a clinical potential of bortezomib in prevention of NK cell-mediated killing of 
pancreatic beta cells in type 1 diabetes patients. 
 
In the following study, we aimed at evaluating potential effects of proteasome 
inhibition by bortezomib on death receptor-mediated functions. We chose two MM cell 
lines as target cells, since bortezomib was first approved for the treatment of patients 
with MM (Richardson and Anderson 2003). FasL/Fas and TRAIL/TRAIL-R mainly 
contribute to the death receptor-mediated pathways by NK cells (Falschlehner, et al 
2009). Herein, we demonstrated that bortezomib signiﬁcantly downregulates TRAIL 
expression in IL-2-activated NK cells, and suppresses perforin-independent killing 
activity of activated NK cells against human MM cells. Moreover, the inhibitory effect 
by bortezomib seems to be selective as the expression of FasL as well as perforin was 
not impaired at the same condition. TRAIL expression level on resting NK cells in 
blood is low or undetectable, but it is inducible upon stimulation of Th1 type cytokines 
including IL-2, interferon (IFN)-γ, and IL-15 (Smyth, et al 2003), to this notion, we 
used IL-2 activated NK cells in this study. Several studies have shown that TRAIL 
induces apoptosis in MM cells in vitro (Balsas, et al 2009, Lincz, et al 2001). Moreover, 
recombinant soluble TRAIL induced MM cell apoptosis and protected against MM 
cell-induced lytic bone destruction in a mouse model (Labrinidis, et al 2009). These 
studies indicated that a disruption of TRAIL expression may impair its cytotoxicity 
against MM. 
 
The NF-κB pathway seems to be involved in the regulation of NKp46 expression after 
bortezomib treatment (paper I). Consistently, our data showed that Bay11-7082 
signiﬁcantly reduced the expression of TRAIL both at the mRNA and protein level, 
indicated that proteasome inhibition regulates TRAIL expression at transcriptional level, 
and the NF-ҡB pathway plays a key role in the regulation of TRAIL expression in 
activated human NK cells. NK cell cytotoxicity applied in paper I is classical short-
term (4 h) lysis assay. However, in paper II we utilized a long-term (12 h) 
51
Cr release 
assay, plus CMA pretreatment to exclude perforin-dependent pathway (Phillips and 
Lanier 1986). Using this modiﬁed assay, we could demonstrate that bortezomib 
treatment signiﬁcantly suppressed LAK or NK cell-mediated killing of human MM cell 
lines. Moreover, the lysis of RPMI8226 cells, which expressed high level of DR4 and 
DR5, were partially, but significantly blocked by anti-TRAIL antibody, indicating that 
TRAIL is involved in the NK cell-mediated killing of RPMI8226 cells. Further studies 
are warranted to clarify the underlying mechanisms by which bortezomib disrupts NK 
cell cytotoxicity towards RPMI8226 cells besides impairing TRAIL-mediated pathway. 
 
In paper III, we studied a small molecule b-AP15, which is an inhibitor of proteasome 
deubiquitination, and its pro-apoptotic effect on MM cells and human primary NK cells. 
Bortezomib is used as a first-line therapy for multiple myeloma patients (Goldberg 
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2012); however, relapse often occurs in patients who initially responded to bortezomib. 
Moreover, the cytotoxic effect of this drug to immune-component cells, including its 
side effect on NK cells (paper I and paper II), makes the use of bortezomib a 
complicated issue (Buac, et al 2012). Thus, basic research needs to explore novel 
proteasome inhibitors, which could provide better therapeutic effects but with less side 
effects. One recent publication gave an opportunity to study the novel proteasome 
inhibitor b-AP15, which differs from bortezomib insofar as it acts through inhibition of 
the 19S regulatory-particle associated deubiquitinases (DUBs) (D'Arcy, et al 2011). We 
observed dose- and time-dependent apoptosis of MM cells induced by b-AP15, in line 
with the accumulation of polyubiquitin, as well as activation of caspase-3 and cleavage 
of its downstream substrate PARP, indicating that caspase-dependent pathways might 
be involved in this process. In fact, our studies showed that b-AP15 triggered caspase-
dependent apoptosis in MM cells. 
 
In paper I, we demonstrated that proteasome inhibitor bortezomib influence NK cell 
survival at the dose below clinically used doses in myeloma patients. In paper III, we 
noted that b-AP15 induces apoptosis of purified human NK cells at doses equal to or 
lower to the doses that killed MM cells, further confirming our previous observation in 
paper I that NK cells are sensitive to proteasome inhibition. However, more 
interestingly, we found that b-AP15 was less toxic to NK cells than bortezomib. It will 
be of interest to determine whether this is a common feature of DUB inhibitors and 
whether this translates into less adverse effects on immune cells in vivo. Of course, it 
remains to be investigated whether NK cell-mediated killing activity is also impaired 
after exposing NK cells to b-AP15. 
 
In the last paper, we studied the regulatory effect of multi-functional protein HAX-1 on 
MM cells. The reason to study the function of HAX-1 in MM is due to our finding that 
HAX1 mRNA expression is high in multiple myeloma, even higher than the previous 
reported high expression in B lymphomas (Kwiecinska, et al 2011). HAX-1 was 
initially believed to be an anti-apoptotic protein. A very important evidence of this 
notion is the discovery of patients with genetic defects of HAX1 gene, which is 
associated with severe congenital neutropenia (also known as Kostmann disease), in 
which HAX-1 was shown to display a role of preventing myeloid stem cell from 
apoptosis in the bone marrow (Carlsson, et al 2004). Moreover, the HAX-1-interacting 
protein HS-1 also plays an important role in B cell receptor (BCR)-mediated apoptosis 
and proliferative responses (Taniuchi, et al 1995). Therefore, knocking down of HAX-
1 expression on MM cell lines with siRNA as well as a control siRNA was applied to 
achieve the aims of studying its putative anti-apoptotic function. However, we noted 
that silencing of HAX-1 expression in MM cell lines does not affect sensitivity to the 
apoptotic stimuli, bortezomib or b-AP15 applied in this study.  
 
Han et al. (2010) reported granzyme B-mediated cleavage of HAX-1 and identified 
HAX-1 cleavage as a novel mechanism for granzyme B-mediated mitochondrial 
depolarization (Han, et al 2010). We corroborated the observation that recombinant 
granzyme B is able to cleave HAX-1 using MM cells and we reported for the first time 
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that NK cells can mediate granzyme B-mediated cleavage of HAX-1 in target cells. 
However, we could not demonstrate a role for HAX-1 in the regulation of target cell 
susceptibility to NK cell killing using the standard 4 h 
51
Cr release assay. Since HAX-1 
has been shown to interact with several viral proteins (Kawaguchi, et al 2000, Sharp, et 
al 2002, Yedavalli, et al 2005), its cleavage could serve to prevent such interactions, 
thereby affecting virus function(s), this remains to be studied. 
 
HAX-1 is a multi-functional protein (Fadeel and Grzybowska 2009) and recent 
publications also revealed its role in the regulation of cell migration (Mekkawy, et al 
2012, Ramsay, et al 2007). We applied fibronectin coated Transwell assay to study a 
possible role of HAX-1 in the regulation of migration activity of MM cells. Our data 
demonstrated that inhibition of HAX-1 expression in the U266 cell line significantly 
decreased its migration ability to specific chemoattractant, SDF-1α. Of note, silencing 
of HAX-1 in MM cells did not trigger apoptosis, indicating that the reduced migration 
was not due to an increase in cell death. It was known that expression of CXCR4, the 
receptor for SDF-1α, is decreased in B cells from HAX-1-deficient mice (Peckl-Schmid, 
et al 2010). Moreover, Dobreva et al described the physical interaction of HAX-1 and 
integrin-linked kinase (ILK), a kinase known to participate in integrin signaling, 
including regulation of integrin-mediated cell migration (Dobreva, et al 2008). We 
detected surface expression of CXCR4, and integrin receptors, α4, α5 and β1, using 
specific antibodies and flow cytometry based analysis. However, we could not detect a 
reduction of surface expression of CXCR4 on U266 cells after silencing of HAX-1, nor 
did we detect a decrease in expression of integrin receptors, α4, α5 and β1. Ramsay et al 
pointed out in their study that HAX-1 regulates carcinoma cell migration and invasion 
via clathrin-mediated endocytosis of integrin alphavbeta6 (Ramsay, et al 2007). 
However, our experiments only provided the surface expression of these molecules 
after HAX-1 deletion. One could further study the endocytosis of these receptors after 
HAX-1 knockdown. We also want to assess HAX-1 protein expression in MM patient 
biopsies using immunohistochemical techniques and it will be of interest to determine 
if HAX-1 expression correlates with the biological/clinical behavior of the tumor in 
patients. 
 
We believe that the results generated in this thesis will improve our knowledge of 
proteasome inhibition in the regulation of NK cell function. We aim to provide 
important knowledge for designing a more effective proteasome inhibitor-based 
treatment for patients with multiple myeloma, with the goal to maintain proteasome 
inhibition-associated apoptosis induction activity in tumor cells, with reduction of the 
toxic effects of proteasome inhibition on immune cells including NK cells. Moreover, 
we have observed that HAX-1 is overexpressed in MM and played a role in the 
regulation of myeloma cell migration, which might point to HAX-1 as a potential target 
in the treatment of myeloma. Overall, our studies should serve to improve the clinical 
management of patients with MM, and may also aid in the understanding of the utility 
of proteasome inhibition in the treatment of other types of cancer. 
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6 CONCLUSIONS 
 
In summary, the main results generated from the studies suggest the following: 
 
Paper I: 
 Bortezomib induces resting NK cell apoptosis in a time- and dose-dependent 
manner. 
 
 Glutathione, a reactive oxygen species scavenger, protects against bortezomib-
induced apoptosis in resting natural killer cells.  
 
 Bortezomib reduces activating receptor NKp46 expression as well as NK cell 
cytotoxicity mediated through the NKp46 activation pathway. 
 
 Bay 11-7082, a pharmacological inhibitor of NF-κB activation, also reduces 
NKp46 expression and suppressed redirected cytotoxicity. 
 
Paper II: 
 Bortezomib selectively reduces the surface expression of TRAIL in activated 
human NK cells. 
 
 Perforin-independent killing of MM cell lines is impaired by bortezomib at 
doses that does not induce apoptosis of NK cells or MM cells. 
 
 The anti-TRAIL antibody blocks the lysis of TRAIL sensitive RPMI8226 cells. 
 
Paper III: 
 The novel proteasome inhibitor, b-AP15 induces caspase-dependent apoptosis 
of human MM cells. 
 
 b-AP15 induces apoptosis in primary human NK cells. 
 
 The pro-apoptotic effect of b-AP15 on NK cells is not as pronounced as the 
effect of bortezomib. 
 
Paper IV: 
 HAX-1 is highly expressed in MM cells. 
 
 HAX-1 does not seem to play a role in regulation of apoptosis in MM cells. 
 
 HAX-1 is shown here to play a role in the regulation of myeloma cell migration. 
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